B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

NUAK1

MOLECULAR TARGET

NUAK family kinase 1

UniProt: O60285NCBI Gene: 989125 compounds

NUAK1 (NUAK family kinase 1) is targeted by 25 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting NUAK1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1tozasertib4.3375
2bosutinib4.0858
3midostaurin3.8546
4brigatinib3.8144
5neratinib3.6638
6nintedanib3.6136
7tae 6843.4330
8fedratinib3.4029
9dovitinib3.0921
10jnj 77066213.0921
11lestaurtinib3.0420
12ruboxistaurin2.9418
13r 4062.8316
14pha 6657522.7114
15gsk 6906932.6413
16bx 7952.4010
17bms 7548072.309
18su 0148132.208
19prexasertib2.087
20maleimide1.956
21bastadin 71.956
22cerdulatinib1.956
23sra 7371.956
24norlichexanthone1.795
25Quercetin0.691

About NUAK1 as a Drug Target

NUAK1 (NUAK family kinase 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 25 compounds with documented NUAK1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

NUAK1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.